An innovative research effort has found that providing pluripotent cells to unborn babies affected by spina bifida while undergoing fetal surgery can be a "important advancement" in managing prenatal disorders.
Research Framework and Assurance
The US-based trial involved six developing infants with the 'open' form of spina bifida. Doctors administered mother's placental stem cells on the exposed area of the baby's spinal cord while the defect was being closed.
Critically, the stem cell application proved to be secure. The study team reported that the treatment did not lead to tumors, hinder surgical recovery, or impede the resolution of related neurological issues.
Positive Developments
Magnetic resonance imaging performed on the newborns showed a successful correction of hindbrain herniation in each of the babies. This favorable anatomical change is strongly associated with better mobility and function.
"Should it enable a greater number of infants able to walk who otherwise would not, then it would become the conventional approach," said the lead researcher. "The results are super exciting and create a pathway toward lots of potential novel therapies."
Broader Impact and Encouragement
Commentators reviewing the findings have suggested that further confirmation of these apparent benefits could herald a "new era" in in-utero treatment. The potential to improve nerve function impairment present before birth is considered a paradigm-shifting aim.
Notably important would be advancements for continence and digestive health, which are common challenges for individuals living with this condition.
Looking Ahead
Despite this being a first-in-human effort was small in scale, its safety demonstration and positive signals offer a robust platform for larger, more comprehensive studies. The integration of stem cell therapy with established fetal surgery techniques presents significant potential for changing life trajectories for future generations with this neural tube defect.